A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia (FOXY)
Study of Intranasal Oxytocin for Frontotemporal Dementia (FOXY)
Sponsor: Canadian Institutes of Health Research
Enrolling: Male and Female Patients
Study Length: 6 Months
Clinic Visits: 5
IRB Number: AAAR7205
U.S. Govt. ID: NCT03260920
Contact: Colin Stein: 212-304-7943 / cs4125@cumc.columbia.edu
Additional Study Information: Columbia Medical Center is recruiting for a study to test whether the drug oxytocin can improve symptoms of emotion and behavior (e.g. apathy) in people with frontotemporal dementia. The study will last for up to 24 weeks (6 months). This is a crossover study, which means that each participant will receive both oxytocin and placebo (medically inactive substance). Over the course of three months, the participant will come in five times with a study partner, who may be a family member or friend, for medical, behavioral and cognitive assessment. There will be a blood draw at each visit, and an optional lumbar puncture (spinal tap) at two visits. Each visit will last 3-5 hours. Participation and transportation costs will be reimbursed.
This study is closed
Edward Huey, MD
Do You Qualify?
Do you currently have a diagnosis of frontotemporal dementia (FTD) (including bvFTD, Semantic Dementia, and PPA)? Yes No
Is there a person you are close with who can accompany you to visits? Yes No
Do you have symptoms such as decreased motivation or emotional connectivity? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Colin Stein